I nfliximab (IFX) is a monoclonal antibody against tumor necrosis factor alpha and is commonly used as a first-line agent for the treatment of moderate-to-severe Crohn's disease (CD) and ulcerative colitis. IFX is given every 4 to 8 weeks as an intravenous (IV) infusion in either a hospital-based or outpatient infusion center. Although IFX is an excellent steroid-sparing agent to induce and maintain mucosal remission in patients with inflammatory bowel disease (IBD), side effects include infection, malignancy, and most commonly, acute infusion reactions. 1 Acute IFX infusion reactions can be mild or severe, with symptoms ranging from erythema or pruritus at the IV site, to fever, dyspnea, chest pain, hypotension, and even anaphylaxis. 2 Acute infusion reactions occur within the first 24 hours after the infusion. 3 The mechanism of these reactions remains unclear; limited data argue against a type 1 hypersensitivity reaction, as IgE-mediated allergic reactions typically require presensitization and a small study looking at the pathogenesis of IFX reactions found normal serum IgE levels after acute infusion reactions. 1, 4 Although evidence directs against IgE-mediated reactions, many providers use premedications in an attempt to prevent acute infusion reactions. 1, 2 Premedication strategies often include steroids, antihistamine drugs such as diphenhydramine, and antipyretics such as acetaminophen. In addition, some centers may give prehydration with normal saline or lactated Ringer solution. Data supporting the use of premedications are limited with no clear evidence regarding who should receive premedications and which agents are best when premedications are deemed necessary. Picoraro et al 2 showed significant interpractice and intrapractice variability in premedication use before IFX infusions in patients with IBD and concluded that clinical practices are generally based on individual or group preference instead of evidence. Small retrospective studies looking at effectiveness of premedication use for patients with rheumatologic conditions had inconsistent results. Choqeutte et al 5 demonstrated that neither systemic corticosteroids, antihistamines nor acetaminophen had a benefit in preventing acute infusion reactions in those with rheumatologic conditions, whereas Bartoli et al 6 found certain combinations of premedications effective at preventing IFX reactions. In addition, a small study in patients with CD found no benefit of IV hydrocortisone use in preventing acute infusion reactions. 7 Given the significant variability in clinical practice and the paucity of high-quality evidence, we aimed to evaluate the effectiveness of various premedications in the prevention of acute IFX infusion reactions. The primary objective of this study was to identify the rate of acute IFX infusion reactions in clinical practice as well as whether the administration of premedications was associated with a lower rate of infusion reactions. Secondarily, we determined whether premedications affected the rate of infusion reactions among patients risk stratified as low or high risk.
MATERIALS AND METHODS
We conducted a single center retrospective cohort study of patients with IBD receiving IFX infusions. A search query performed using i2b2, 8 a patient cohort discovery tool, identified patients with a diagnosis of IBD (identified using ICD-9 billing codes 556, 555.9, and 558.9) who were treated with IFX in the outpatient infusion center from January 1, 2008, to January 12, 2016 . The use of IFX was identified using both a NormRX code and an institution-specific drug code. Patients younger than 18 years and those who received IFX at an outside institution were excluded.
Basic demographic information, including age, sex, type of IBD, ethnicity, smoking status, drug allergies, food allergies, and medical and surgical history was collected. Medications used before the initiation of IFX and those taken during the IFX course were recorded. Previous IFX use, if any, and reason for cessation, including loss of response, noncompliance, or change in insurance coverage were noted. For every IFX infusion, the date, dosage, time over which the infusion was given, and the number of weeks from the previous infusion were documented. The use of premedications, which was at the discretion of the treating physician, was recorded, including the type of medication, dose, and delivery method. Finally, any hydration given before the IFX infusion was documented.
All acute IFX infusion reactions were recorded. This included the symptoms, treatment provided, need for emergency medical services, and need for hospitalization. All the reactions were initially identified by our dedicated infusion nurses in the IBD center and confirmed by an IBD physician on site at the time of the reaction. Reaction severity was graded based on previously identified definitions of mild, moderate, and severe reactions. 9 Mild reactions were defined as self-limited and resolved with temporary cessation of the infusion. Moderate reactions were those that required an extended observation period and generally required discontinuation of the infusion. Severe reactions included respiratory symptoms or changes in vital signs with a need for close medical follow-up. 9 ,10 Details about the management of patients who had an acute IFX infusion reaction were recorded. As per our institution's protocol, management included either continuation of IFX with modifications to the premedication strategy or use of a different biological agent. All delayed infusion reactions (defined as those reactions occurring 1-14 days after the infusion) were excluded.
To control for possible selection bias of patients at high risk for an acute infusion reaction receiving premedications, we FIGURE 1. Inclusion and exclusion criteria for patients in this study. ICD-9 billing codes included 556, 555.9, and 558.9. stratified infusions into high and low risk. High-risk infusions were those in which the patient had a previous IFX reaction, there was a delay between infusions (defined as 10 or more weeks from the previous infusion), or the IFX was reintroduced after a drug holiday (defined by 20 weeks or more between infusions). 11, 12 Low-risk infusions were those who did not have any of the high-risk characteristics defined above.
In both the high-and low-risk cohort, we compared the reaction rate among patients receiving premedications as compared to those who did not receive premedications. Given that premedications often differed for each infusion and that a reaction could occur in 1 infusion and then not recur for the same patient, each infusion was considered a single event and both the risk stratification and the reaction rate were determined by infusion. A 2-tailed Fisher's exact test and chi-squared test were used to analyze categorical variables, whereas a Student's T test was used for continuous variables. The relative risk was also calculated for each premedication combination seen in our institution. Statistical significance was set at an alpha of 0.05, and confidence intervals were calculated for all relative risks. All statistical analyses were conducted using R and R studio (Version 3.2.2; Boston, MA).
RESULTS
We identified 773 patients using the i2b2 search, and 578 (74.8%) fulfilled inclusion criteria (Fig. 1) . Overall, the mean age was 38.8 years (range 19-86 yrs) and 307 (53.1%) were women. Three hundred thirty (57.1%) had a diagnosis of CD, 244 (42.2%) had ulcerative colitis, and 3 (0.5%) had indeterminate colitis. Three hundred nineteen (55.2%) patients were receiving an oral mesalamine, 11 (19.2%) a thiopurine (azathioprine or 6-mercaptopurine). Two hundred twenty (38.1%) patients were concomitantly prescribed a steroid, of which 69 (11.9%) were on prednisone (with a mean dose of 7.8 mg), 70 (12.1%) were prescribed budesonide (Entocort), 26 (4.5%) were prescribed budesonide (Uceris), and 55 (9.5%) were prescribed a steroid enema. Fifty-four (9.3%) patients were reintroduced to IFX after a drug holiday for various reasons: 4 (7.4%) had a previous reaction to the drug, 21 (38.9%) had previously lost response to IFX, 19 (37.0%%) preferred not to continue infusions, and 6 (11.1%) had unknown reasons. Overall, 230 (39.8%) patients had an allergy to 1 or more medications before starting IFX and 5 (0.9%) had a history of drug-related anaphylaxis. Baseline characteristics are reported in Table 1 ; there was no significant difference between patients who received premedications and those who did not (Table 1) . Concurrent immunomodulater use was not associated with a statistically significant decrease in the number of acute IFX infusion reactions (P ¼ 0.073). Likewise, neither the concurrent use of systemic steroids nor topical steroids such as budesonide were associated with fewer acute IFX infusion reactions (P ¼ 0.317, P ¼ 0.591 respectively).
Of the 578 patients in this study, 7090 total infusions were identified. One thousand one hundred nineteen (15.7%) were AZA, azathioprine; 6-mp, 6-mercaptopurine; PPI, proton pump inhibitor.
induction doses and 5971 (84.2%) were maintenance doses. The dose of IFX ranged from 5 to 20 mg/kg, with a mean of 9.2 mg/kg and a median of 5 mg/kg. Six thousand nine hundred eight-four (98.5%) infusions were administered over 2 hours (with a graded infusion protocol), 67 (0.9%) over 3 hours, 33 (0.4%) over 4 or more hours. Two thousand eight hundred seventy-three (40.5%) infusions were administered with premedications (Table 2) . Premedications included oral (25 mg) or IV (25 or 50 mg) diphenhydramine and IV hydrocortisone (125 mg). In addition, 4333 (61.1%) infusions were administered with concomitant prehydration, which was defined by 250 mL of normal saline given over 30 minutes before the IFX infusion ( Table 2) . None of the patients in our institution received oral steroids or oral acetaminophen. One hundred fourteen (1.6%) acute IFX infusion reactions were identified (Table 3) . A description of these reactions, their management, and outcomes are described in Table 3 . The incidence of severe infusion reactions did not differ between the high-and lowrisk groups (P ¼ 0.971).
Of the 7090 infusions in the study, 986 (13.9%) infusions were identified as high risk for an acute IFX infusion reaction. Two hundred sixty-two (26.5%) of these infusions were considered high risk because of a previous reaction to IFX, 299 (30.3%) had a delay between infusions, and 519 (52.6%) were reintroduced to IFX after a drug holiday. Among this highrisk cohort, 128 (12.9%) were induction doses, and the mean dose of IFX was 9.7 mg/kg. Six hundred twenty (62.8%) infusions in the high-risk cohort were administered with premedications and 53 (5.4%) reactions were identified (Table 4 ). In the high-risk group, the reaction rate for infusions given with premedication was not statistically different from the reaction rate with no premedications, P ¼ 0.971. More specifically, there was no significant difference found in the reaction rate for any of the premedication combinations used compared with no premedication use. When oral and IV formulations of diphenhydramine were combined in the high-risk group, the results remained nonsignificant. Table 4 lists each premedication strategy in the high-risk group and its relative risk compared with no premedication use. Finally, the use of concomitant prehydration with or without other premedications in the high-risk group did not reduce the rate of reaction when compared with no premedication use (Table 5) .
Likewise, 6104 (86.1%) were stratified as low risk for an acute IFX infusion reaction. Nine hundred ninety-one (16.2%) infusions were induction doses, and the mean dose of IFX was 8.7 mg/kg. Two thousand two hundred fifty-three (36.9%) of infusions in the low-risk group received premedications and 61 (1.0%) reactions were identified. In the low-risk group, the reaction rate for infusions given with any premedication was not statistically different from the reaction rate with no premedication, P ¼ 0.763. More specifically, there was no significant difference found in the reaction rate for any of the premedication combinations used compared with no premedication use. When oral and IV formulations of diphenhydramine were combined in the low-risk group, the results remained nonsignificant. Table 4 lists each premedication strategy in the lowrisk group, and its relative risk compared with no premedication use. In addition, the use of concomitant prehydration with or without other premedications in the low-risk group did not reduce the rate of reaction when compared with no premedication use (Table 5) .
DISCUSSION
This is the largest study to date evaluating the effectiveness of premedications in preventing acute IFX infusion reactions in the IBD population. We report a 1.6% acute infusion reaction rate, with a rate of 5.6% in the high-risk group and 1.0% in the low-risk cohort. This study demonstrates that premedications are not associated with a significant reduction in acute IFX infusion reactions. A paradoxical increase in the number of infusion reactions for those who received certain premedications was initially identified, but by risk stratifying the infusions, this confounder was removed. By risk stratifying the cohort, we were able to show that even in high-risk infusions, which are so often premedicated due to an overwhelming concern for an acute infusion reaction, premedication use was not associated with a significantly lower rate of acute IFX infusion reactions. Together, these findings call into question the pervasive clinical use of these agents today.
Although rare, acute IFX infusion reactions are a significant concern for both clinicians and patients given the potential need to stop IFX therapy and the limited number of agents available today to treat moderate-to-severe IBD. To date, there is minimal literature on premedication use to prevent acute IFX infusion reactions. Most studies focus on the etiology and management of infusion reactions, acknowledging the empiric use of premedications without substantial evidence. A systematic review on IFX-related infusion reactions concluded that premedication with corticosteroids, antipyretics, and/or antihistamines, while frequently done, lacks controlled validation. 1 Although 1 study found that the use of premedications including a combination of paracetamol, hydoxyzine, 6 methylprednisolone, and ranitidine in patients receiving IFX for rheumatologic conditions resulted in a reduced rate of infusion reactions, other studies contradict these data. A large Canadian study evaluating the IFX use in patients with arthritis found that antihistamines, IV steroids, and acetaminophen did not prevent acute IFX infusion reactions. 5 In addition, a small study investigating patients with CD also found no benefit of IV hydrocortisone use in preventing acute infusion reactions. 7 The only prospective trial on premedication use showed that betamethasone did not reduce the incidence or intensity of infusion reactions in patients with arthritis receiving IFX. 13 Most recently, a study was published acknowledging the significant amount of interpractice and intrapractice variability in premedication use. 2 Although antihistamines such as diphenhydramine and steroids such as hydrocortisone are commonly used as premedications, our study is unique in that it also looked at the effect of prehydration on acute infusion reactions. The use of normal saline or lactated Ringer solution before the IFX infusion is not commonly seen in the IBD literature, but is more common with other infusions such as IV immunoglobulin or methotrexate. 14, 15 Interestingly, in the high-risk group, use of prehydration alone did reduce the rate of reaction compared with those who received no premedication, although this difference did not reach statistical significance. The mechanism of this effect remains unclear, and future studies on prehydration as a strategy for reducing IFX infusion reactions would be needed to clarify this relationship.
In addition, none of the studies above discussed the timing of premedication use before the IFX infusion. Corticosteroids must traverse the cell membrane and enter the cell nucleus to suppress inflammatory genes. This process can take hours, explaining the drug's delayed effect in acute allergic reactions. Furthermore, although the onset of IV diphenhydramine is relatively fast, oral diphenhydramine takes up to 60 minutes to be effective. Given this, some clinicians have postulated that premedication strategies to prevent IFX infusion reactions should be modeled after premedication algorithms for iodine-based contrast allergies, many of which include either oral or IV steroids given 13, 7, and 1 hour before injection of the dye. 16 In this study, premedication including diphenhydramine and hydrocortisone were documented as being given either immediately before the start of the IFX or up to 10 minutes before the infusion. Given the pharmocokinetics of these agents combined with the fact that most infusion reactions occur early on in the infusion (most reactions in this study occurred within the first 15 min of the infusion), perhaps these medications did not reduce the reaction rate in this study because they were given too close to the infusion and were not allowed sufficient time to take effect. The use of premedications, such as antihistamines and corticosteroids, is not inconsequential. Many of these medications are associated with side effects, including drowsiness, blurry vision, upset stomach, and decreased mental alertness. For patients who must drive to their infusions, the use of diphenhydramine can prolong the time they must remain in the infusion center or require them to have another individual accompany them to the infusion. Finally, the use of high dose steroids is not desirable in a patient population that is often chronically exposed to steroids to treat their underlying disease.
This study has several potential limitations. Given the retrospective nature, we were reliant on electronic documentation of the administration of premedications and any subsequent infusion reactions. Moreover, we could only evaluate premedication strategies used at our institution. Although a prospective study on premedication use would be ideal, the feasibility of this is unclear given the very low reaction rate and subsequent large number of patients who would need to be enrolled over time. In addition, given the lack of randomization, confounders may have influenced our results. We accounted for this by riskstratifying patients and associated infusions but additional confounders could be present. In addition, we did not document any adverse effects from the premedications given. It is possible that some of the reaction symptoms seen were either partially or completely due to the premedication used and not due to the IFX. However, only reactions that occurred after the initiation of the IFX were recorded. Furthermore, given the nature of our IBD referral practice, with a substantial group of high-risk patients who have experienced multiple exposures to biologics and previous reactions, our reaction rate may be higher than many community centers calling into question the generalizability of our results. However, we accounted for this by risk-stratifying infusions for those at high risk for having a reaction. In addition, this study was limited to acute IFX infusion reactions and did not evaluate the effect of premedications on delayed infusion reactions. Given that delayed infusion reactions are thought to occur from a different underlying mechanism compared with acute infusion reactions and that there is significant variability in the reporting of delayed infusion reactions by patients, it was thought that delayed infusion reactions would best be analyzed in a separate study. Finally, the results of this study are from a single, academic center in a large urban area, possibly reducing the generalizability of the findings.
This study also has several strengths. First, this is the largest study to date looking at premedication use with IFX infusions in patients with IBD. In addition, we improved on previous studies by risk-stratifying patients into high-and low-risk groups, to try and eliminate potential selection bias, which may have resulted in the paradoxical increase in the reaction rates seen in previous studies. Moreover, our patients received infusions at a dedicated IBD infusion center staffed by a trained infusion nurse, with standardized documentation of both premedication use and infusion reactions, helping to strengthen our internal validity. Finally, the additional analysis on the effect of prehydration on acute IFX infusion reactions has never before been reported in the published IBD literature.
In conclusion, using a large retrospective cohort, we did not find a statistical difference in the rate of acute IFX infusion reactions as a result of premedication use, including diphenhydramine, hydrocortisone, and IV fluids in both high-and low-risk infusions. Although there may be circumstances in which premedication use should be considered on an individual basis, given the lack of effectiveness demonstrated in this study, we would not recommend routine premedication use without future randomized control trials to demonstrate efficacy.
